Focused on AIDD (Artificial Intelligence Drug Discovery) as its core technological engine, Huitai Biomedicine leverages proprietary core algorithms and a global intellectual property portfolio to precisely target the unmet clinical needs in fibrotic diseases.
Currently, we are developing a groundbreaking new drug aimed at treating Idiopathic Pulmonary Fibrosis (IPF) by targeting the activation of TGF-β1. Notably, there are no comparable competitors globally. This drug has successfully completed Phase I clinical trials in Beijing, China. We are now preparing to submit a first-in-class new drug clinical trial application to the FDA.
